Tocilizumab does not ameliorate inflammation-induced left ventricular dysfunction in a collagen-induced arthritis rat model
These results suggest that although IL-6 blockade by tocilizumab may prevent inflammation-induced collagen cross-linking, the current treatment regimen may not protect against inflammation-induced LV dysfunction. Therefore, the role of IL-6 in the molecular mechanisms of inflammation-induced LV dysfunction remains inconclusive.
Authors
- Ashmeetha Manilall (ORCID: https://orcid.org/0000-0002-1215-052X)
- Lebogang Mokotedi (ORCID: https://orcid.org/0000-0002-1520-7093)
- Serena Fourie
- Regina Le Roux (ORCID: https://orcid.org/0000-0003-1806-1760)
- Sulè Gunter (ORCID: https://orcid.org/0000-0002-1711-5934)
- Aletta ME. Millen
Institutions
- University of the Witwatersrand (ZA)
Publication Details
- Journal
- Cardiovascular Pathology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1016/j.carpath.2024.107711
- Citations
- 2
- Primary Topic
- Cardiac Fibrosis and Remodeling
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- National Research Foundation